Dacomitinib in advanced lung cancer: Disadvantages outweigh survival advantage
Since its approval in April 2019, dacomitinib has been available for the first-line treatment of adult patients with locally advanced
Read more
Since its approval in April 2019, dacomitinib has been available for the first-line treatment of adult patients with locally advanced
Read more